Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Given Average Recommendation of “Hold” by Brokerages

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has been given a consensus rating of “Hold” by the five ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.1667.

Several research firms have recently issued reports on ADIL. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Monday, April 20th. Brookline Capital Markets downgraded shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Loop Capital set a $6.00 price objective on shares of Adial Pharmaceuticals in a research note on Monday, June 15th. Finally, Needham & Company LLC cut shares of Adial Pharmaceuticals to a “buy” rating in a report on Monday, June 15th.

Insider Buying and Selling

In other Adial Pharmaceuticals news, major shareholder Coastlands Capital Lp bought 25,000 shares of Adial Pharmaceuticals stock in a transaction on Monday, June 29th. The shares were purchased at an average cost of $2.60 per share, for a total transaction of $65,000.00. Following the completion of the acquisition, the insider owned 373,322 shares in the company, valued at approximately $970,637.20. The trade was a 7.18% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.86% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ADIL. Armistice Capital LLC acquired a new stake in shares of Adial Pharmaceuticals during the fourth quarter worth $562,000. Citadel Advisors LLC acquired a new position in Adial Pharmaceuticals in the 3rd quarter worth $51,000. Finally, Jane Street Group LLC increased its holdings in Adial Pharmaceuticals by 887.3% during the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after purchasing an additional 109,500 shares in the last quarter. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Stock Down 2.4%

ADIL stock opened at $2.80 on Friday. The business’s fifty day moving average is $2.27 and its 200-day moving average is $2.97. The company has a market cap of $5.99 million, a P/E ratio of -0.35 and a beta of 1.43. Adial Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $18.90.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its quarterly earnings data on Friday, May 8th. The company reported ($1.48) EPS for the quarter, topping analysts’ consensus estimates of ($2.73) by $1.25.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.